🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🥁🥁Introducing🥁🥁 *** #ASCO25 BINGO!! ** FRIDAY ROUND UP! Click here to claim your bingo card! 👇🏽 👇🏽 bingodoc.emergent.host #OnlyOncologistsInTheBuilding W/Emil Lou, MD, PhD, FACP Shruti Patel, MD, and thanks to Ankit kansagra for building the prototype for this app!

Honored to get the 2025 OncoDaily mentorship Yvonne Award from the one and only Petros Grivas. And in the presence of the crew that matters the most who came and supported! Amin Nassar, MD Sagal Pannu Ayesha Aijaz Biagio Ricciuti, MD PhD Hassan Abushukair Alessio Cortellini Faisal, Salman M

Insightful synthesis and discussion by Prof Kevin Harrington The Royal Marsden Cancer Charity The Royal Marsden NHS Foundation Trust comparing and contrasting KN630 and C-POST 💡time to start adj IO 🚨effect of ENI? #ASCO25 Shlomo Koyfman Neil D. Gross, MD, FACS

2nd Plenary #ASCO25: #NIVOPOSTOP Ph III, adj Nivolumab w/ ChemoXRT in high risk squamous cell head & neck ca after surgery. - 3yr DFS: 63.1% vs 52.5% (HR: 0.76). Benefit in all subgroups including CPS/PDL1 - Similar AEs in both arms - Is benefit driven by locations control?

ATOMIC trial shows adjuvant atezolizumab + FOLFOX significantly improves DFS (86.4% vs. 76.6%) vs. FOLFOX alone. This is what federal #Cancer research can do. #ASCO25 #CancerTreatment

#ASCO25 education session on the evolving melanoma treatment landscape 🧬✨ Learn how to navigate care when immunotherapy is contraindicated and identify resistance to immune checkpoint inhibitors early—crucial insights across disease settings! Pauline Funchain Evan Lipson

5th Plenary #ASCO25: #MATTERHORN Ph III, Durvalumab + FLOT—>✂️—>Durva vs NeoAdj FLOT in resectable GEJ/Gastric Ca. - 2yr EFS 67% vs 59% (HR: 0.71). Improvement regardless of PDL1 - 2yr OS 76% vs 70%. mOS NR - Rate of✂️& number of FLOT similar in both arms - D-FLOT new SoC!

MATTERHORN: Perioperative Durvalumab + FLOT vs FLOT alone in resectable G/GEJ adenoca + Taylor Swift quote 🤩 What an awesome way to end the day!! Yelena Y. Janjigian MD #ASCO #ASCO25

“Not everything that counts can be counted. Not everything that can be counted, counts.” -Mark Lewis, MD, FASCO In oncology, metrics matter. But meaning or time or values? You can’t quantify those. That’s why shared decision-making isn’t just a buzzword; it’s the ENTIRE point. #ASCO25

If this were a pill, we’d call it revolutionary. It would headline plenaries, get FDA priority review, and cost $10,000 a month. Instead—it’s structured exercise. 🆕 NEJM June 2025 | CHALLENGE Trial Stage II–III colon cancer patients post-chemo (n=889) 📦 RCT of 3 years of

Alright y’all - last day of #irAE content at #ASCO25 ASPIRE Community of Practice Monday 6/2 11:30a Bi/Multi-specific Antibodies S406 ➡️Giuseppe Curigliano ➡️Enriquita Felip ➡️Funda Meric Bernstam 3p Beyond Checkpoint E450b ➡️me 😇 ➡️Evan Lipson ➡️Jason Luke, MD, FACP

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

Acral melanoma pearls -adjuvant therapy not effective -targeted therapy with responses (not enough data to clearly choose IO vs targeted as 1L imho) -alternative regimens with efficacy in Asia (different biology than US?) Keri Kendra The Ohio State University College of Medicine #ASCO25 #rarecancers

🌉“don’t burn bridges” ➡️ Swiftly moving from no options to what to do in what order with so many options - Marlana Orloff, Thomas Jefferson on metastatic uveal melanoma sequencing strategies #ASCO25 #rarecancers #RareDisease

Powerhouse education session on Rare Melanomas at #ASCO25 covering desmoplastic, acral, uveal, and mucosal by Drs. Kendra, Orloff, and Guo - THE experts in the field. Follow Pauline Funchain for the play by play!

Metastatic mucosal melanoma today: -combination immunotherapy shows lackluster efficacy -MEKi with 25% ORR -KIT + anti PD1 with 54.8% ORR -triplet ICI with 33% ORR -lenv pembro with 50% ORR -TIL with 50% ORR Jun Guo, Beijing Cancer #ASCO25 #raremelanoma #rarecancers #RareDisease

I’ve been in the exercise oncology field for 20 years and for all of that time, the main criticism has been “show me a well controlled RCT.” Well, here it is. Exercise following adjuvant chemotherapy for colon cancer reduced recurrence and improves OVERALL SURVIVAL! #ASCO25

Met Dr Ayesha Aijaz at her poster #67 to learn more about #IO tox ASPIRE Community of Practice and incidence of #granulomatous inflammation. Great mentorship Rafeh Naqash, MD Come by and see her work! #SuppOncSelfies 📸 #ASCO25 Emre Yekedüz Dimitra R. Bakaloudi MD, MS, MPA Andrea Anampa-Guzmán (she/ella) Regina Barragan-Carrillo Corey Speers

For real time updates, follow me at 🦋 (funchainmd.bsky.social) Will update with ICYMI posts here later… #melsm #ASCO25

Wondering what’s involved in structured exercise? Behavioural coaching & hitting 10 MET (metabolic equivalent task) hours per week So that’s like 30min brisk walking 3 times/week 👟 Our standard of providing health info📄 not enough:time to FUND these support programs #ASCO25